Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02691221 · ClinicalTrials.gov registry record · NA
ReliefLink: A Preventative Mobile Toolkit for Follow-Up Care of Psychiatric Patients
A NA study of Suicide, Suicidal Ideation, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT02691221: Completed NA study of Suicide, Suicidal Ideation, sponsored by Emory University.
NCT02691221 is a NA study of Suicide, Suicidal Ideation that has completed, run by Emory University. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02691221, a NA study of Suicide, Suicidal Ideation, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to increase use and availability, as well as assess the feasibility of the ReliefLink (RL) application for use in conjunction with standard care to promote psychological health and prevent suicidal behavior.
Primary Outcome
A comprehensive, semi-structured interview measure that uniquely measures the full spectrum of suicidality including passive and active suicidal ideation, suicidal intent as well as suicidal behaviors. It rates an individual's degree of suicidal ideation on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." A higher number of "yes" responses indicated an increased degree of suicidal ideation.
Conditions Studied
Interventions
- BEHAVIORAL Relief Link Application Daily Tasks
Study Locations (1)
Georgia
- Grady Health System - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2016-04 |
| Est. Completion | 2017-10 |
| Phase | NA |
What the finished NCT02691221 record still lists
NCT02691221 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Suicide, Suicidal Ideation appearing as the primary indexed condition, and to 1 intervention - of which Relief Link Application Daily Tasks is the first listed.
NCT02691221 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT02691221 about?
NCT02691221 is a clinical study titled "ReliefLink: A Preventative Mobile Toolkit for Follow-Up Care of Psychiatric Patients". The purpose of this study is to increase use and availability, as well as assess the feasibility of the ReliefLink (RL) application for use in conjunction with standard care to promote psychological health and prevent suicidal behavior.
What is the current status of trial NCT02691221?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2016-04. Estimated completion is 2017-10.
What conditions does trial NCT02691221 study?
This clinical trial studies the following conditions: Suicide, Suicidal Ideation.
What interventions are being tested in trial NCT02691221?
The interventions under investigation include: Relief Link Application Daily Tasks (BEHAVIORAL).
Who is sponsoring clinical trial NCT02691221?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02691221 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02691221's enrollment target sits among peer trials
13 1911th of 2000 higher than 88 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia